{"id":56145,"date":"2023-04-24T17:03:49","date_gmt":"2023-04-24T15:03:49","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/dyve-biosciences-presents-preclinical-data-from-lead-oncology-drug-candidate-dyv800-at-the-american-association-for-cancer-research-2023-annual-meeting\/"},"modified":"2023-04-24T17:03:49","modified_gmt":"2023-04-24T15:03:49","slug":"dyve-biosciences-presents-preclinical-data-from-lead-oncology-drug-candidate-dyv800-at-the-american-association-for-cancer-research-2023-annual-meeting","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/dyve-biosciences-presents-preclinical-data-from-lead-oncology-drug-candidate-dyv800-at-the-american-association-for-cancer-research-2023-annual-meeting\/","title":{"rendered":"Dyve Biosciences Presents Preclinical Data from Lead Oncology Drug Candidate, DYV800, at the American Association for Cancer Research 2023 Annual Meeting"},"content":{"rendered":"
\n

\nPre-clinical data supports DYV800, a pH modulating agent that targets tumor microenvironment (TME) acidity in solid tumors. DYV800, delivered topically to bypass gastrointestinal absorption challenges, neutralizes the TME acidity that plays a strong role in tumor progression.<\/i><\/p>\n

CAMARILLO, Calif.–(BUSINESS WIRE)–#biotechnology<\/a>—Dyve Biosciences<\/a>, Inc. (\u201cDyve\u201d), a clinical-stage platform biotechnology company with assets in immunology and oncology, today announced the summary results of a poster presentation from the on-going preclinical partnership with the H. Lee Moffitt Cancer Center & Research Institute<\/a> (\u201cMoffitt\u201d) showing preclinical data from the company\u2019s unique delivery approach that unlocks the powerful effects of neutralizing the TME acidity.<\/p>\n

<\/a><\/p>\n

\nThe poster, presented in collaboration with Moffitt, showcased data demonstrating the delivery of intuitive, targeted pH modulation to treat solid tumors. Tumor acidosis plays a major role in tumor aggressiveness, invasion, and resistance and is an important target for novel anticancer strategies. In the presentation, Dyve and Moffitt demonstrated for the first time that the extracellular pH of tumors can be increased upon application of a buffer formulation delivered transdermally, bypassing the GI tract and unlocking a more viable route to TME buffering therapy in oncology.<\/p>\n

\n\u201cDyve continues to advance research in areas where our pH modulation program can unlock decades of \u2018settled science\u2019 using our proprietary delivery technology. Our transdermal alkalinization treatment induced pH changes in a murine melanoma model as measured with MRI-CEST pH imaging and demonstrated for the first time that the extracellular pH of tumors can be increased upon application of a buffer formulation delivered transdermally. We are eager to translate these promising results into the clinic, including through our strategic alliance with Moffitt, and believe the on-going studies will continue to validate our approach and ultimately benefit patients across a number of different tumor types.\u201d \u2013 Ryan Beal, M.D.<\/a>, CEO, Dyve Biosciences<\/i><\/p>\n

\nThe research was published in AACR Journals and is available here: https:\/\/aacrjournals.org\/cancerres\/article\/83\/7_Supplement\/2391\/721916<\/a><\/p>\n

\nAbout Dyve Biosciences, Inc.<\/b><\/p>\n

\nDyve Biosciences (\u201cDyve\u201d) is a clinically validated biotech that is breaking barriers to deliver on the promise of pH modulation. Decades of published research demonstrate that neutralizing microenvironment acidity profoundly impacts disease, with multi-fold improvements in tumor metastases, cancer survival, and immune response. Leveraging our groundbreaking DMAX delivery platform, Dyve\u2019s science directly targets the acidic microenvironments that drive cancer cell growth and inflammation. Dyve has demonstrated that it can deliver intuitive, targeted pH modulation to treat oncologic and immuno-inflammatory diseases.<\/p>\n

\nLearn more at www.dyvebio.com<\/a>.<\/p>\n

Contacts<\/b> <\/p>\n

\nCorporate & Investor Contact:
\n
Jim McGee<\/a>
Dyve Biosciences, Inc.
\n
833-398-3246
\n
jim.mcgee@dyvebio.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Pre-clinical data supports DYV800, a pH modulating agent that targets tumor microenvironment (TME) acidity in solid tumors. DYV800, delivered topically to bypass gastrointestinal absorption challenges, neutralizes the TME acidity that plays a strong role in tumor progression. CAMARILLO, Calif.–(BUSINESS WIRE)–#biotechnology—Dyve Biosciences, Inc. (\u201cDyve\u201d), a clinical-stage platform biotechnology company with assets in immunology and oncology, today … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-56145","6":"format-standard","7":"category-industry"},"yoast_head":"\nDyve Biosciences Presents Preclinical Data from Lead Oncology Drug Candidate, DYV800, at the American Association for Cancer Research 2023 Annual Meeting - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/dyve-biosciences-presents-preclinical-data-from-lead-oncology-drug-candidate-dyv800-at-the-american-association-for-cancer-research-2023-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dyve Biosciences Presents Preclinical Data from Lead Oncology Drug Candidate, DYV800, at the American Association for Cancer Research 2023 Annual Meeting - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Pre-clinical data supports DYV800, a pH modulating agent that targets tumor microenvironment (TME) acidity in solid tumors. DYV800, delivered topically to bypass gastrointestinal absorption challenges, neutralizes the TME acidity that plays a strong role in tumor progression. CAMARILLO, Calif.–(BUSINESS WIRE)–#biotechnology—Dyve Biosciences, Inc. (\u201cDyve\u201d), a clinical-stage platform biotechnology company with assets in immunology and oncology, today ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/dyve-biosciences-presents-preclinical-data-from-lead-oncology-drug-candidate-dyv800-at-the-american-association-for-cancer-research-2023-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-24T15:03:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230424005377\/en\/1771716\/21\/Dyve_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dyve-biosciences-presents-preclinical-data-from-lead-oncology-drug-candidate-dyv800-at-the-american-association-for-cancer-research-2023-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dyve-biosciences-presents-preclinical-data-from-lead-oncology-drug-candidate-dyv800-at-the-american-association-for-cancer-research-2023-annual-meeting\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Dyve Biosciences Presents Preclinical Data from Lead Oncology Drug Candidate, DYV800, at the American Association for Cancer Research 2023 Annual Meeting\",\"datePublished\":\"2023-04-24T15:03:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dyve-biosciences-presents-preclinical-data-from-lead-oncology-drug-candidate-dyv800-at-the-american-association-for-cancer-research-2023-annual-meeting\\\/\"},\"wordCount\":444,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dyve-biosciences-presents-preclinical-data-from-lead-oncology-drug-candidate-dyv800-at-the-american-association-for-cancer-research-2023-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230424005377\\\/en\\\/1771716\\\/21\\\/Dyve_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dyve-biosciences-presents-preclinical-data-from-lead-oncology-drug-candidate-dyv800-at-the-american-association-for-cancer-research-2023-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dyve-biosciences-presents-preclinical-data-from-lead-oncology-drug-candidate-dyv800-at-the-american-association-for-cancer-research-2023-annual-meeting\\\/\",\"name\":\"Dyve Biosciences Presents Preclinical Data from Lead Oncology Drug Candidate, DYV800, at the American Association for Cancer Research 2023 Annual Meeting - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dyve-biosciences-presents-preclinical-data-from-lead-oncology-drug-candidate-dyv800-at-the-american-association-for-cancer-research-2023-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dyve-biosciences-presents-preclinical-data-from-lead-oncology-drug-candidate-dyv800-at-the-american-association-for-cancer-research-2023-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230424005377\\\/en\\\/1771716\\\/21\\\/Dyve_Logo.jpg\",\"datePublished\":\"2023-04-24T15:03:49+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dyve-biosciences-presents-preclinical-data-from-lead-oncology-drug-candidate-dyv800-at-the-american-association-for-cancer-research-2023-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dyve-biosciences-presents-preclinical-data-from-lead-oncology-drug-candidate-dyv800-at-the-american-association-for-cancer-research-2023-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dyve-biosciences-presents-preclinical-data-from-lead-oncology-drug-candidate-dyv800-at-the-american-association-for-cancer-research-2023-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230424005377\\\/en\\\/1771716\\\/21\\\/Dyve_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230424005377\\\/en\\\/1771716\\\/21\\\/Dyve_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dyve-biosciences-presents-preclinical-data-from-lead-oncology-drug-candidate-dyv800-at-the-american-association-for-cancer-research-2023-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Dyve Biosciences Presents Preclinical Data from Lead Oncology Drug Candidate, DYV800, at the American Association for Cancer Research 2023 Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Dyve Biosciences Presents Preclinical Data from Lead Oncology Drug Candidate, DYV800, at the American Association for Cancer Research 2023 Annual Meeting - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/dyve-biosciences-presents-preclinical-data-from-lead-oncology-drug-candidate-dyv800-at-the-american-association-for-cancer-research-2023-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Dyve Biosciences Presents Preclinical Data from Lead Oncology Drug Candidate, DYV800, at the American Association for Cancer Research 2023 Annual Meeting - Pharma Trend","og_description":"Pre-clinical data supports DYV800, a pH modulating agent that targets tumor microenvironment (TME) acidity in solid tumors. DYV800, delivered topically to bypass gastrointestinal absorption challenges, neutralizes the TME acidity that plays a strong role in tumor progression. CAMARILLO, Calif.–(BUSINESS WIRE)–#biotechnology—Dyve Biosciences, Inc. (\u201cDyve\u201d), a clinical-stage platform biotechnology company with assets in immunology and oncology, today ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/dyve-biosciences-presents-preclinical-data-from-lead-oncology-drug-candidate-dyv800-at-the-american-association-for-cancer-research-2023-annual-meeting\/","og_site_name":"Pharma Trend","article_published_time":"2023-04-24T15:03:49+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230424005377\/en\/1771716\/21\/Dyve_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/dyve-biosciences-presents-preclinical-data-from-lead-oncology-drug-candidate-dyv800-at-the-american-association-for-cancer-research-2023-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/dyve-biosciences-presents-preclinical-data-from-lead-oncology-drug-candidate-dyv800-at-the-american-association-for-cancer-research-2023-annual-meeting\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Dyve Biosciences Presents Preclinical Data from Lead Oncology Drug Candidate, DYV800, at the American Association for Cancer Research 2023 Annual Meeting","datePublished":"2023-04-24T15:03:49+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/dyve-biosciences-presents-preclinical-data-from-lead-oncology-drug-candidate-dyv800-at-the-american-association-for-cancer-research-2023-annual-meeting\/"},"wordCount":444,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/dyve-biosciences-presents-preclinical-data-from-lead-oncology-drug-candidate-dyv800-at-the-american-association-for-cancer-research-2023-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230424005377\/en\/1771716\/21\/Dyve_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/dyve-biosciences-presents-preclinical-data-from-lead-oncology-drug-candidate-dyv800-at-the-american-association-for-cancer-research-2023-annual-meeting\/","url":"https:\/\/pharma-trend.com\/en\/dyve-biosciences-presents-preclinical-data-from-lead-oncology-drug-candidate-dyv800-at-the-american-association-for-cancer-research-2023-annual-meeting\/","name":"Dyve Biosciences Presents Preclinical Data from Lead Oncology Drug Candidate, DYV800, at the American Association for Cancer Research 2023 Annual Meeting - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/dyve-biosciences-presents-preclinical-data-from-lead-oncology-drug-candidate-dyv800-at-the-american-association-for-cancer-research-2023-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/dyve-biosciences-presents-preclinical-data-from-lead-oncology-drug-candidate-dyv800-at-the-american-association-for-cancer-research-2023-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230424005377\/en\/1771716\/21\/Dyve_Logo.jpg","datePublished":"2023-04-24T15:03:49+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/dyve-biosciences-presents-preclinical-data-from-lead-oncology-drug-candidate-dyv800-at-the-american-association-for-cancer-research-2023-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/dyve-biosciences-presents-preclinical-data-from-lead-oncology-drug-candidate-dyv800-at-the-american-association-for-cancer-research-2023-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/dyve-biosciences-presents-preclinical-data-from-lead-oncology-drug-candidate-dyv800-at-the-american-association-for-cancer-research-2023-annual-meeting\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230424005377\/en\/1771716\/21\/Dyve_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230424005377\/en\/1771716\/21\/Dyve_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/dyve-biosciences-presents-preclinical-data-from-lead-oncology-drug-candidate-dyv800-at-the-american-association-for-cancer-research-2023-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Dyve Biosciences Presents Preclinical Data from Lead Oncology Drug Candidate, DYV800, at the American Association for Cancer Research 2023 Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/56145","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=56145"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/56145\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=56145"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=56145"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=56145"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}